Lightchain Bioscience

Lightchain Bioscience is a Swiss clinical-stage biotechnology company focused on the discovery and development of next-generation bispecific antibodies. The company utilizes its proprietary κλ-body platform to create fully human bispecific antibodies that maintain the native structure of a standard IgG, facilitating easier manufacturing and favorable drug-like properties. Lightchain's pipeline primarily targets oncology and inflammatory diseases, with lead programs focusing on hematological malignancies and solid tumors. The company was formed following the restructuring of Novimmune and continues to leverage its deep expertise in antibody engineering. Its lead partnered asset, TG-1701, is currently in clinical development for B-cell malignancies.